bio, again, I ask (since you didn’t answer) what other processes do you think are prevented from happening while the cells sit in the EDEN culture cartridge for the first five days? I think this gets to the heart of the supposed 10x production gains. (beyond those I mentioned)
The process that I constructed was based on the process and equipment that I speculated on months ago, and was confirmed in the ASCO presentation, and in pictures, which I assume were from around April/May. That appears (to me) to be the first iteration of the original version of the EDEN system, and the hypothetical process used the seven new pieces of equipment that I speculated potentially could have been installed for an initial production line to demonstrate Advent’s ability to manufacture DCVax in compliance with commercial GMP.
I do have manufacturing experience, and during an executive MBA course, I toured Nissan and Toyota car factories in Vietnam, China, and Japan, clothing factories from top designers in Vietnam, Hong Kong, and China, POSCO Steel, and Samsung electronic’s factories in S. Korea, (and others) and met with US government and foreign trade reps in each of those countries.
I was not imagining the eventual industrial commercial process, but rather, the initial, current commercial process developed by Advent for the commercial license application. But perhaps you could enlighten us simpletons :) What do you think are the seven pieces of automated equipment installed, and how would the commercial manufacturing process work?